-- One-Year Follow-Up Results Confirm Significant
Efficacy and No Serious Adverse Effects in Patients Using CELZ-001
for Treating Type 2 Diabetes --
PHOENIX,
April 12,
2023 /PRNewswire/ -- Creative Medical Technology
Holdings, Inc. ("Creative Medical Technology" or the "Company")
(NASDAQ: CELZ), a leading biotechnology company focused on a
regenerative approach to immunotherapy, urology, gynecology, and
orthopedics, today announced positive one-year follow-up data and
significant efficacy using CELZ-001 to treat patients with Type 2
Diabetes without any serious adverse effects reported.
There were no safety concerns related to CELZ-001
at one year follow-up utilizing the same infusion procedure as in
the currently U.S. FDA cleared CELZ-201 clinical trial. There were
30 patients in the study, 15 who received CELZ-001 and the rest
received optimized medical therapy. At one year, there was an
overall efficacy of 93% in the treated patients demonstrating at
least a 50% reduction in insulin requirement. The Company plans to
further develop this program and present the findings at an
upcoming endocrinology conference.
"The positive one-year data from our Type 2
diabetes study is very encouraging, and we are excited to engage
with clinicians in further translation," said Timothy Warbington, President and CEO of the
Company. "Creative Medical Technology Holdings has a unique
portfolio with multiple cell-based approaches that can potentially
help patients with early-stage Type 1 Diabetes - CELZ-201, Brittle
Type 1 Diabetes - CELZ-101, and late-stage Type 2 Diabetes -
CELZ-001."
About Type 2 Diabetes*
More than 37
million Americans have diabetes (about 1 in 10), and approximately
90-95% of them have type 2 diabetes. Type 2 diabetes most often
develops in people over age 45, but more and more children, teens,
and young adults are also developing it. In Type 2 diabetes, the
body has insulin resistance which is managed by diet and exercise
along with oral medical therapy help maintain adequate glucose
levels. However, as the disease progresses, patients also require
insulin along with other oral and injectable therapies. Diabetes is
the eighth leading cause of death in the
United States with over 96 million US adults have
prediabetes, and more than 8 in 10 of them don't know they have
it.
About Creative Medical Technology
Holdings
Creative Medical Technology Holdings, Inc. is a
biotechnology company dedicated to the advancement of identifying
and translating novel biological therapeutics in the fields of
immunotherapy, endocrinology, urology, gynecology and orthopedics
and is traded on NASDAQ under the ticker symbol CELZ. For further
information about the Company, please
visit www.creativemedicaltechnology.com.
Forward Looking Statements
This news
release may contain forward-looking statements including but not
limited to comments regarding the timing and content of upcoming
clinical trials and laboratory results, marketing efforts, funding,
etc. Forward-looking statements address future events and
conditions and, therefore, involve inherent risks and
uncertainties. Actual results may differ materially from those
currently anticipated in such statements. See the periodic and
other reports filed by Creative Medical Technology Holdings, Inc.
with the Securities and Exchange Commission and available on the
Commission's website at www.sec.gov.
*
www.cdc.gov/diabetes/basics/quick-facts.html
View original content to download
multimedia:https://www.prnewswire.com/news-releases/creative-medical-technology-announces-positive-top-line-results-for-type-2-diabetes-study-301795119.html
SOURCE Creative Medical Technology Holdings, Inc.